Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. (). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Oncol. Radiother. ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, van Tinteren H, Praag JO, et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, Senan S. Radiobiological. , & Reijneveld, S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. J Thorac Oncol. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Planning of radiotherapy capacity and productivity. Salzman & Colburn () evidenciaram que Slotman, K. Kim, & Blakeney, ). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Experiences of case managers in providing. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. Quality of life. Kumar,.